Citation: | XU Han, ZHANG Yuanyuan, KOU Junping. Advances in drug-induced gastrointestinal bleeding and its pathological mechanism[J]. Journal of China Pharmaceutical University, 2019, 50(6): 659-665. DOI: 10.11665/j.issn.1000-5048.20190604 |
[1] |
Aoki T,Hirata Y,Yamada A,et al.Initial management for acute lower gastrointestinal bleeding[J].World J Gastroenterol,2019,25(1):69-84.
|
[2] |
Ur-Rahman A,Guan J,Khalid S,et al.Both full Glasgow-blatchford score and modified Glasgow-blatchford score predict the need for intervention and mortality in patients with acute lower gastrointestinal bleeding[J].Dig Dis Sci,2018,63(11):3020-3025.
|
[3] |
Sengupta N,Cifu AS.Management of patients with acute lower gastrointestinal tract bleeding[J].JAMA,2018,320(1):86-87.
|
[4] |
Yuan JQ,Tsoi KK,Yang M,et al.Systematic review with network meta-analysis:comparative effectiveness and safety of strategies for preventing NSAID-associated gastrointestinal toxicity[J].Aliment Pharmacol Ther,2016,43(12):1262-1275.
|
[5] |
Chi TY,Zhu HM,Zhang M.Risk factors associated with nonsteroidal anti-inflammatory drugs(NSAIDs)-induced gastrointestinal bleeding resulting on people over 60 years old in Beijing[J].Medicine(Baltimore),2018,97(18):e0665.
|
[6] |
Park J,Jeon SR,Kim JO,et al.Rebleeding rate and risk factors in nonsteroidal anti-inflammatory drug-induced enteropathy[J].J Dig Dis,2018,19(5):279-287.
|
[7] |
Chen WC,Lin KH,Huang YT,et al.The risk of lower gastrointestinal bleeding in low-dose aspirin users[J].Aliment Pharmacol Ther,2017,45(12):1542-1550.
|
[8] |
García Rodríguez LA,Martín-Pérez M,Hennekens CH,et al.Bleeding risk with long-term low-dose aspirin:a systematic review of observational studies[J].PLoS One,2016,11(8):e0160046.
|
[9] |
Sostres C, Carrera-Lasfuentes P, Lanas A. Non-steroidal anti-inflammatory drug related upper gastrointestinal bleeding:types of drug use and patient profiles in real clinical practice[J].Curr Med Res Opin,2017,33(10):1815-1820.
|
[10] |
Chan FK,Leung Ki EL,Wong GL,et al.Risks of bleeding recurrence and cardiovascular events with continued aspirin use after lower gastrointestinal hemorrhage[J].Gastroenterology,2016,151(2):271-277.
|
[11] |
Figueiras A,Estany-Gestal A,Aguirre C,et al.CYP2C9 variants as a risk modifier of NSAID-related gastrointestinal bleeding:a case-control study[J].Pharmacogenet Genomics,2016,26(2):66-73.
|
[12] |
Mo C,Sun G,Lu ML,et al.Proton pump inhibitors in prevention of low-dose aspirin-associated upper gastrointestinal injuries[J].World J Gastroenterol,2015,21(17):5382-5392.
|
[13] |
Lué A,Lanas A.Protons pump inhibitor treatment and lower gastrointestinal bleeding:balancing risks and benefits[J].World J Gastroenterol,2016,22(48):10477-10481.
|
[14] |
Colucci R,Pellegrini C,Fornai M,et al.Pathophysiology of NSAID-associated intestinal lesions in the rat:luminal bacteria and mucosal inflammation as targets for prevention[J].Front Pharmacol,2018,9:1340.
|
[15] |
Yokoe S,Nakagawa T,Kojima Y,et al.Indomethacin-induced intestinal epithelial cell damage is mediated by pVHL activation through the degradation of collagen I and HIF-1α[J].Biochem Biophys Res Commun,2015,468(4):671-676.
|
[16] |
Lichtenberger LM,Bhattarai D,Phan TM,et al.Suppression of contractile activity in the small intestine by indomethacin and omeprazole[J].Am J Physiol Gastrointest Liver Physiol,2015,308(9):G785-G793.
|
[17] |
Mayo SA,Song YK,Cruz MR,et al.Indomethacin injury to the rat small intestine is dependent upon biliary secretion and is associated with overgrowth of enterococci[J].Physiol Rep,2016,4(6):e12725.
|
[18] |
Amagase K,Nakamura E,Kato S,et al.Glutamate as a potential protective drug in the gastrointestinal mucosa[J].Yakugaku Zasshi,2015,135(6):779-782.
|
[19] |
Lai Y,Zhong W,Yu T,et al.Rebamipide promotes the regeneration of aspirin-induced small-intestine mucosal injury through accumulation of β-catenin[J].PLoS One,2015,10(7):e0132031.
|
[20] |
Majeed A,Wallvik N,Eriksson J,et al.Optimal timing of vitamin K antagonist resumption after upper gastrointestinal bleeding.A risk modelling analysis[J].Thromb Haemost,2017,117(3):491-499.
|
[21] |
Verdecchia P,Vedovati MC,Conti S,et al.Long-term outcome in patients with non-valvular atrial fibrillation on dabigatran:a prospective cohort study[J].Expert Opin Drug Saf,2018,17(11):1063-1069.
|
[22] |
Bartlett JW,Renner E,Mouland E,et al.Clinical safety outcomes in patients with nonvalvular atrial fibrillation on rivaroxaban and diltiazem[J].Ann Pharmacother,2019,53(1):21-27.
|
[23] |
Gieling EM,van den Ham HA,van Onzenoort H,et al.Risk of major bleeding and stroke associated with the use of vitamin K antagonists,nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation:a cohort study[J].Br J Clin Pharmacol,2017,83(8):1844-1859.
|
[24] |
Sherid M,Sulaiman S,Samo S,et al.Risk of gastrointestinal bleeding with rivaroxaban:a comparative study with warfarin[J].Gastroenterol Res Pract,2016,2016:9589036.
|
[25] |
Go AS,Singer DE,Toh S,et al.Outcomes of dabigatran and warfarin for atrial fibrillation in contemporary practice:a retrospective cohort study[J].Ann Intern Med,2017,167(12):845-854.
|
[26] |
Graham DJ,Reichman ME,Wernecke M,et al.Cardiovascular,bleeding,and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation[J].Circulation,2015,131(2):157-164.
|
[27] |
Mirkov I,Popov AA,Demenesku J,et al.Intestinal toxicity of oral warfarin intake in rats[J].Food Chem Toxicol,2016,94:11-18.
|
[28] |
Fahmy AI, Mekkawy MA, Abou-Ali A. Evaluation of adverse events involving bleeding associated with oral P2Y12 inhibitors use in the food and drug administration adverse event reporting system[J].Int J Clin Pharmacol Ther,2019,57(4):175-181.
|
[29] |
Yang C,Qian J,Tang X,et al.Meta-analysis on the efficacy and adverse events of aspirin plus clopidogrel versus aspirin-monotherapy in patients with ischemic stroke or transient ischemic attack[J].Chin J Epidemiol(中华流行病学杂志),2015,36(12):1430-1435.
|
[30] |
Nishtala PS,Jamieson HA,Hanger HC,et al.Examining the risks of major bleeding events in older people using antithrombotics[J].Cardiovasc Drugs Ther,2019,33(3):323-329.
|
[31] |
Patel P,Nigam N,Sengupta N.Lower gastrointestinal bleeding in patients with coronary artery disease on antithrombotics and subsequent mortality risk[J].J Gastroenterol Hepatol,2018,33(6):1185-1191.
|
[32] |
Oakland K,Desborough MJ,Murphy MF,et al.Rebleeding and mortality after lower gastrointestinal bleeding in patients taking antiplatelets or anticoagulants[J].Clin Gastroenterol Hepatol,2019,17(7):1276-1284.
|
[33] |
Lucotti S,Cerutti C,Soyer M,et al.Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1/thromboxane A2[J].J Clin Invest,2019,129(5):1845-1862.
|
[34] |
Luo JC,Peng YL,Chen TS,et al.Clopidogrel inhibits angiogenesis of gastric ulcer healing via downregulation of vascular endothelial growth factor receptor 2[J].J Formos Med Assoc(台湾医学会杂志),2016,115(9):764-772.
|
[35] |
Li JJ,Wu XY,Chen JL,et al.Antiplatelet drug ticagrelor delays gastric ulcer healing in rats[J].Exp Ther Med,2017,14(4):3774-3779.
|
[36] |
Chisti MM,Khachani A,Brahmanday GR,et al.Dasatinib-induced haemorrhagic colitis in chronic myeloid leukaemia(CML)in blast crisis[J].BMJ Case Rep,2013,2013:2013200610.
|
[37] |
Kreutzman A,Colom-Fernández B,Jiménez AM,et al.Dasatinib reversibly disrupts endothelial vascular integrity by increasing non-muscle myosin II contractility in a ROCK-dependent manner[J].Clin Cancer Res,2017,23(21):6697-6707.
|
[38] |
Wang ML,Blum KA,Martin P,et al.Long-term follow-up of MCL patients treated with single-agent ibrutinib:updated safety and efficacy results[J].Blood,2015,126(6):739-745.
|
[39] |
Zhu XQ,Tian XL,Yu CY,et al.Increased risk of hemorrhage in metastatic colorectal cancer patients treated with bevacizumab:an updated meta-analysis of 12 randomized controlled trials[J].Medicine(Baltimore),2016,95(34):e4232.
|
[40] |
Kroschinsky F,Stölzel F,von Bonin S,et al.New drugs,new toxicities:severe side effects of modern targeted and immunotherapy of cancer and their management[J].Crit Care,2017,21(1):89.
|
[41] |
Gonzales P,Klusewitz S,Marowske J,et al.Everolimus implicated in case of severe gastrointestinal hemorrhage[J].Case Rep Oncol Med,2017,2017:3657812.
|
[42] |
Assi H,Abdel-Samad N.Severe gastrointestinal hemorrhage during targeted therapy for advanced breast carcinoma[J].Curr Oncol,2014,21(5):e732-e735.
|
[43] |
Tsuchihashi K,Shimokawa H,Takayoshi K,et al.Regorafenib-induced retinal and gastrointestinal hemorrhage in a metastatic colorectal cancer patient with liver dysfunction:a case report[J].Medicine(Baltimore),2017,96(42):e8285.
|
[44] |
Burcu B,Kanter M,Orhon ZN,et al.Protective effects of vitamin E on methotrexate-induced jejunal mucosal damage in rats[J].Anal Quant Cytopathol Histpathol,2016,38(2):87-94.
|
[45] |
Frank M,Hennenberg EM,Eyking A,et al.TLR signaling modulates side effects of anticancer therapy in the small intestine[J].J Immunol,2015,194(4):1983-1995.
|
[46] |
Gao J,Gao J,Qian L,et al.Activation of p38-MAPK by CXCL4/CXCR3 axis contributes to p53-dependent intestinal apoptosis initiated by 5-fluorouracil[J].Cancer Biol Ther,2014,15(8):982-991.
|
[47] |
Araújo RS,Silveira ALM,de Sales E Souza éL,et al.Intestinal toxicity evaluation of long-circulating and pH-sensitive liposomes loaded with cisplatin[J] Eur J Pharm Sci,2017,106:142-151.
|
[48] |
Cai ZY,Yang W,He YY,et al.Cefoperazone/sulbactam-induced abdominal wall hematoma and upper gastrointestinal bleeding:a case report and review of the literature[J].Drug Saf-Case Rep,2016,3(1):2.
|
[49] |
Katukuri GR,Maddala RN,Ramamoorthi K,et al.Cefoperazone induced gastrointestinal bleeding[J].J Clin Diagn Res,2016,10(8):OD10-OD11.
|
[50] |
Wan Q, Cheng RY, Guo JW, et al. Effect of ceftriaxone on the intestinal epithelium and Microbiota in neonatal mice[J].Chin J Contemp Pediatr(中国当代儿科杂志),2018,20(4):318-325.
|
[51] |
Fotouhie A,Desai H,Parsa NA,et al.Gastrointestinal bleeding secondary to trimethoprim sulfamethoxazole-induced vitamin K deficiency[J].BMJ Case Rep,2016,2016:2016214437.
|
[52] |
Hsu SC,Chang SS,Lee MG,et al.Risk of gastrointestinal perforation in patients taking oral fluoroquinolone therapy:an analysis of nationally representative cohort[J].PLoS One,2017,12(9):e0183813.
|
[53] |
Yuet WC, Derasari D, Sivoravong J, et al. Selective serotonin reuptake inhibitor use and risk of gastrointestinal and intracranial bleeding[J].J Am Osteopath Assoc,2019,119(2):102-111.
|
[54] |
Patel H,Gaduputi V,Sakam S,et al.Serotonin reuptake inhibitors and post-gastrostomy bleeding:reevaluating the link[J].Ther Clin Risk Manag,2015,11:1283-1289.
|
[55] |
Narum S,Westergren T,Klemp M.Corticosteroids and risk of gastrointestinal bleeding:a systematic review and meta-analysis[J].BMJ Open,2014,4(5):e004587.
|
[56] |
Tomizawa M,Shinozaki F,Hasegawa R,et al.Immunosuppressive agents are associated with peptic ulcer bleeding[J].Exp Ther Med,2017,13(5):1927-1931.
|
[57] |
Jerebtsova M, Das JR, Tang PT, et al. Angiopoietin-1 prevents severe bleeding complications induced by heparin-like drugs and fibroblast growth factor-2 in mice[J].Am J Physiol Heart Circ Physiol,2015,309(8):H1314-H1325.
|
[58] |
Qasim M,Rahman H,Ahmed R,et al.Mycophenolic acid mediated disruption of the intestinal epithelial tight junctions[J].Exp Cell Res,2014,322(2):277-289.
|